Acute myeloblastic leukaemia in the elderly: Biology, prognostic factors and treatment

International Journal of Hematology

Volumn 68, Issue 3, 1998, Pages 235-243

  Manoharan, Arumugam ^a  

^a ST GEORGE HOSPITAL   (Australia)

Author keywords

Acute myeloblastic leukaemia; Elderly patients

Indexed keywords

CYTARABINE; ETOPOSIDE; MITOXANTRONE; TIOGUANINE;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; AGING; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOPOIESIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

EID: 0031784262     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0925-5710(98)00050-4     Document Type: Review

References (48)

1. Burnett A.K., Eden O.B. The treatment of acute leukaemia. Lancet. 349:1997;270-275.
2. Brincker H. Estimates of overall treatment results in acute non-lymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep. 69:1985;5-11.
3. Butler R.N. Population aging and health. Br Med J. 315:1997;1082-1084.
4. Slapak C.A., Desforges J.F., Fogaren T., Miller K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea and calcitriol. Am J Hematol. 61:1992;178-183.
5. Frenette P.S., Desforges J.F., Schenkein D.P., Rabson A., Slapak C.A., Miller K.B. Granulocyte macrophage colony stimulating factor (GM-CSF) priming in the treatment of elderly patients with acute myelogenous leukemia. Am J Hematol. 49:1995;48-55.
6. Kuriya S.I., Murai K., Miyairi Y.et al. A combination chemotherapy with low doses of cytarabine and etoposide for high risk myelodysplastic syndromes and their leukemic stage. Cancer. 78:1996;422-426.
7. Tsurumi H., Yamada T., Hara T.et al. Continuous infusion therapy with low dose cytosine arabinoside and etoposide in acute myelogenous leukemia patients hardly tolerable for intensive chemotherapy. Int J Hematol (Abstr). 64(Suppl 1):1996;5169.
8. Manoharan A., Baker R.I., Kyle P.W. Low-dose combination chemotherapy for acute myeloid leukemia in elderly patients: a novel approach. Am J Hematol. 55:1997;115-117.
9. Lichtman MA. Acute myelogenous leukemia. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, editors. Williams Hematology. New York: McGraw-Hill, 1995:272-98.
10. Hamblin T.J. Disappointments in treating acute leukemia in the elderly. New Engl J Med. 332:1995;1712-1713.
11. Spataro V., Delacretaz F., Schmidt P.M., Cometta A., Kovacsovics T.J. Intensive treatment of AML in the elderly: influence of trilineage myelodysplasia and of pre-existing myelodysplastic syndrome on clinical outcome. Blood (Abstr). 88(Suppl 1):1996;559a.
12. Johnson P.R.E., Liu Yin J.A. The influence of clinical or morphological myelodysplasia on the outcome of therapy in elderly patients with acute myeloid leukaemia. Haematologica (Abstr). 76(Suppl 4):1991;511.
13. Hamblin T.M. The treatment of acute myeloid leukaemia preceded by the myelodysplastic syndrome. Leuk Res. 16:1992;101-108.
14. Yunis J.J., Lobell M., Arnesen M.A.et al. Refined chromosome study helps define prognostic subgroups in most patients with primary myelodysplastic syndrome and acute myelogenous leukaemia. Br J Haematol. 68:1988;189-194.
15. Dastugue N., Payen C., Lafage-Pochitaloff M.et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. Leukemia. 9:1995;1491-1498.
16. Leith C.P., Kopecky K.J., Godwin J.et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study. Blood. 89:1997;3323-3329.
17. Wood P., Burgess R., MacGregor A., Liu J.A. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol. 87:1994;509-514.
18. Xie X.Y., Robb D., Chow S., Hedley D.W. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia. Leukemia. 9:1995;1882-1887.
19. List A.F., Spier S.C., Grogan T.M.et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464-2469.
20. Minden M., Imrie K., Keating A. Acute leukemia in adults. Curr Opin Hematol. 3:1996;259-265.
21. Fialkow P.J., Singer J.W., Raskind W.H.et al. Clonal development, stem cell differentiation and clinical remissions in acute non-lymphocytic leukemia. New Engl J Med. 317:1987;468-473.
22. Sebban C., Archimbaud E., Coiffier B.et al. Treatment of acute myeloid leukemia in elderly patients. Cancer. 61:1988;227-231.
23. Johnson P.R.E., Hunt L.P., Liu Yin J.A. Prognostic factors in elderly patients with acute myeloid leukaemia: development of a model to predict survival. Br J Haematol. 85:1993;300-306.
24. Ferrara F., Mirto S. Serum LDH value as a predictor of clinical outcome in acute myelogenous leukaemia of the elderly. Br J Haematol. 92:1996;627-631.
25. De Lima M., Ghaddar H., Pierce S., Esty E. Treatment of newly diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 93:1996;89-95.
26. Stasi R., Venditti A., Del Poeta G.et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia: analysis of prognostic factors. Cancer. 77:1996;2476-2488.
27. Smith J.G., Fleming P.J.V., Tolliday O.P., Jennison C. Adverse outcome in AML treatment correlates with age and karyotype at presentation: a ten year retrospective audit in a single centre. Blood (Abstr). 88(Suppl 1):1996;169b.
28. Goldstone A.H., Burnett A.K., Wheatley K., Gray R.G. Identification of good risk elderly patients with acute myeloid leukaemia (AML) who benefit from intensive therapy and extremely poor risk ones who do not: prognostic factor analysis of the MRC AML II trial. Blood (Abstr). 88(Suppl 1):1996;291a.
29. Lichtman S.M., Kolitz J., Cirrone K.et al. Comorbidity and age as risk factors for survival in de novo acute leukemia. Blood (Abstr). 88(Suppl 1):1996;166b.
30. Buchner T., Hiddemann W., Loffler H.et al. Treatment of AML in the elderly: full dose versus reduced dose induction treatment. Blood (Abstr). 86(Suppl):1995;434a.
31. Taylor P.R.A., Reid M.M., Stark A.N., Bown N., Hamilton P.J., Proctor S.J. De novo acute myeloid leukaemia in patients over 55-years-old: a population-based study of incidence, treatment and outcome. Leukemia. 9:1995;231-237.
32. Shapiro J., Brown S., Briggs P.et al. Adult acute leukaemia - a retrospective study of 66 consecutive patients. Aust New Zealand J Med. 27:1997;301-306.
33. Lowenberg B. Treatment of the elderly patient with acute myeloid leukaemia. Baillieres Clin Haematol. 9:1996;147-159.
34. Balducci L., Parker M., Sexton W., Tantranond P. Pharmacology of antineoplastic agents in the elderly patient. Semin Oncol. 16:1989;77-84.
35. Solary E., Witz B., Caillot D.et al. Combination of quinine as a potential reversing agent with mitoxantrone and cytarabine for the treatment of acute leukemias: a randomized multicenter study. Blood. 88:1996;1198-1205.
36. Berman E. Recent advances in the treatment of acute leukemia. Curr Opin Hematol. 4:1997;256-260.
37. Keith F.J., Bradbury D.A., Zhu M., Russell N.H. Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to ara-c. Leukemia. 9:1995;131-138.
38. Hu Z., Minden M.D., McCulloch E.A. Direct evidence for the participation of bcl-2 in the regulation of retinoic acid of the ara-c sensitivity of leukemic cells. Leukemia. 9:1995;1667-1673.
39. Baccarini M., Tura S. Differentiation of myeloid leukaemic cells: new possibilities for therapy. Br J Haematol. 42:1979;485-487.
40. Desforges J.F. Cytarabine: low dose, high dose, no dose? New Engl J Med. 309:1983;1637-1639.
41. Leyden M., Manoharan A., Boyd A., Cheng Z.M., Sullivan J. Low-dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction. Br J Haematol. 57:1984;301-307.
42. Tilly H., Castaigne S., Bordessoule D.et al. Low-dose cytarabine versus intensive chemotherapy in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol. 8:1990;272-279.
43. Manoharan A., Leyden M.J., Sullivan J. Low-dose cytarabine in acute myeloid leukaemia. Med J Aust. 141:1984;643-646.
44. Wormann B., Sauerland C., Heinecke A.et al. Prognosis of elderly AML patients excluded from a randomized malticenter trial. Blood (Abstr). 90(Suppl 1):1997;249b.
45. Hande K.R. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Oncologist. 1:1996;234-239.
46. Bonelli G., Sacchi M.C., Barbiero G.et al. Apoptosis of 929 cells by etoposide: a quantitative and kinetic approach. Exp Cell Res. 228:1996;292-305.
47. Sleiman R.J., Catchpoole D.R., Stewart B.W. Drug-induced death of leukaemic cells after G2/M arrest: higher order DNA fragmentation as an indicator of mechanism. Br J Cancer. 77:1998;40-50.
48. Kojima H., Bai A., Hori T., Nagasawa T., Abe T. Role of apoptosis in cytotoxic chemotherapy for acute myelogenous leukemia. Blood (Abstr). 90(Suppl 1):1997;229b.